Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.2945 | 1 | 1 |
Onchocerca volvulus | Glucosylceramidase homolog | 0.0183 | 0.0538 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0193 | 0.0572 | 0.1027 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0279 | 0.0867 | 1 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.2945 | 1 | 1 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.2945 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0279 | 0.0867 | 1 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.2945 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0279 | 0.0867 | 1 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.2945 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0279 | 0.0867 | 1 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.2945 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0279 | 0.0867 | 1 |
Leishmania major | 0.2945 | 1 | 0.5 | |
Toxoplasma gondii | fructose-bisphospatase II | 0.2945 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0193 | 0.0572 | 0.1027 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0279 | 0.0867 | 1 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.2945 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Log 1/D50 (functional) | = 6.06 | Drug concentration in mole/kg/day providing 50% extension of life in intraperitoneally implanted leukemia L1210 mice. | ChEMBL. | 7069706 |
Log 1/LD10 (ADMET) | = 5.58 | Compound concentration in mole/kg/day lethal to 10% of mice | ChEMBL. | 7069706 |
pKa | = 9.88 | Ionization constant (pKa) | ChEMBL. | 7069706 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.